FDA Fast Track Designation: who qualifies and how to write a request that gets accepted

Fast Track is an FDA designation for a drug intended to treat a serious condition when nonclinical or clinical data show its potential to address an unmet medical need. A sponsor requests it with or after the IND, and FDA must answer within 60 calendar days. Requests succeed when they define the condition, prove the gap in available therapy, and present the data plainly in 10 to 20 pages.

What is Fast Track designation and where does it come from?

Section 506(b) of the Federal Food, Drug, and Cosmetic Act directs FDA to facilitate the development and expedite the review of a drug intended to treat a serious or life-threatening disease that demonstrates the potential to address unmet medical needs [1]. Congress added the provision in the FDA Modernization Act, enacted November 21, 1997 [2]. The 2012 FDA Safety and Innovation Act later extended eligibility to qualified infectious disease products [1].

The features are access and sequencing. Fast Track is one of four expedited programs covered by FDA's May 2014 guidance, and the only one a sponsor can earn on nonclinical data alone [3]. A designated program is eligible for more frequent meetings and written communication with the review division, for rolling review of completed application sections, and for priority review if clinical data at submission support it [4].

Who qualifies for Fast Track designation?

The first criterion is a serious condition. FDA borrows the definition from its expanded access regulations: a disease associated with morbidity that has a substantial impact on day-to-day functioning, judged by its effect on survival, functioning, or the likelihood of progression if untreated [3]. A drug aimed at a serious aspect of a condition, such as a serious side effect of available therapy, also qualifies [3].

The second criterion is potential to address that need, and the evidence required scales with stage. Early in development, activity in a nonclinical model, a mechanistic rationale, or pharmacologic data can demonstrate potential; later, clinical data should carry the argument [3]. Where therapy exists, FDA lists what counts: an effect on a serious outcome current drugs do not address, benefit in patients who cannot tolerate or do not respond to them, or comparable efficacy with less serious toxicity [3].

How often does FDA say no?

More often than founders expect. CDER publishes a cumulative count of Fast Track requests, updated in the first quarter of each fiscal year [5]. In fiscal year 2024, CDER received 312 requests, granted 200, and denied 86 [6]. From fiscal 1998 through fiscal 2024, CDER received 3,704 requests and denied 1,042, roughly 28 percent [6].

CBER’s record is similar. Between March 1998 and January 2024, CBER received 814 Fast Track requests and, of those decided, granted 581 and denied 218, a denial rate of roughly 27 percent [7]. Cell, gene, and vaccine programs tend to arrive already aimed at serious diseases with no approved therapy, and even so, more than a quarter of requests fail. Do not plan on a softer standard at either center.

A denial is not final. FDA sends a nondesignation letter stating that designation is not granted and explaining why [3]. A sponsor can request again with new data, and CBER weighs the circumstances of any clinical hold in deciding whether the drug's potential can be assessed [8]. Each cycle costs another 60 days, so a weak first request is expensive.

What should a Fast Track request contain?

FDA's guidance is specific. The cover letter should carry the words REQUEST FOR FAST TRACK DESIGNATION in bold uppercase, with the sponsor contact, IND number, product names, review division, and proposed indication [3]. Then comes a concise summary of the supporting information and a list of documents already in the IND, with submission dates. FDA says the package usually fits in 10 to 20 pages [3].

The summary has two required arguments: the basis for considering the condition serious, and the basis for believing the drug can address an unmet need, together with how the planned development program will evaluate that potential [3]. In my experience, the second half of that sentence is where requests fail. Sponsors argue the biology well but never describe the trial that would show the advantage.

Define available therapy honestly. FDA generally means a therapy approved or licensed in the United States for the same indication and relevant to current standard of care, though in exceptional cases it may count an unapproved use supported by compelling evidence [3]. State the gap as an outcome, such as relapse or treatment-limiting toxicity, then show the data that bear on it and their limits.

Does designation change outcomes? Among 174 novel drugs approved from 2012 to 2016, those with Fast Track had a median clinical development time of 7.0 years versus 8.0 years without it [9]. Across 581 novel drug-indication pairs approved from 2008 to 2021, 34.9 percent used Fast Track [10]. The time saved is real but modest.

How does Fast Track compare with Breakthrough Therapy designation?

Breakthrough therapy designation includes every Fast Track feature and adds intensive FDA guidance and an organizational commitment involving senior managers [11]. The price is evidence: preliminary clinical data showing substantial improvement over available therapy on a clinically significant endpoint [12]. Request Fast Track at IND and Breakthrough once a clinical signal exists, each in its own IND amendment [8].

What does Fast Track not do?

It does not change the approval standard. CBER's own procedure states that designation is not approval and does not alter the statutory standards for safety and effectiveness; the program must still generate substantial evidence of effectiveness [8]. Priority review, a six-month goal rather than ten, is not automatic either. FDA assigns it at filing, based on the application itself [13].

It can be taken away. FDA may rescind Fast Track when the criteria are no longer met, for example when another product gains traditional approval for the same need or emerging data fail to show the expected advantage [3]. CBER sends an intent-to-rescind letter and gives the sponsor 60 days to respond with data or request a meeting [8]. In my reading, rescission means the criteria lapsed, not that the product is unpromising.

What made my own request work?

On a first-in-class biologic for a rare pediatric leukemia, we received FDA IND acceptance and then Fast Track designation two months later. We built the serious-condition argument on survival and relapse in children, and the unmet-need argument on the specific outcome existing therapies failed to address. Every claim pointed to data already in the IND, with the limits of the nonclinical models stated. Designation did not change the trial. It changed how often we talked to the division.

This article is part of the Life Sciences Consulting practice at Hamilton Atlas Group — see the full capability list there.

References

1. U.S. Government Publishing Office. 21 U.S.C. 356 - Expedited approval of drugs for serious or life-threatening diseases or conditions. United States Code, 2023 Edition, govinfo, 2024.
2. U.S. Food and Drug Administration. Food and Drug Administration Modernization Act (FDAMA) of 1997. FDA, 2018.
3. U.S. Food and Drug Administration. Expedited Programs for Serious Conditions | Drugs and Biologics. Guidance for Industry, FDA, 2014.
4. U.S. Food and Drug Administration. Fast Track. FDA, 2024.
5. U.S. Food and Drug Administration. Fast Track Designation Requests. FDA, 2025.
6. U.S. Food and Drug Administration. CDER Fast Track Designation Requests Received, Fiscal Year 1998 - Fiscal Year 2024. FDA, 2025.
7. U.S. Food and Drug Administration. Fast Track Designation Request Performance. CBER, FDA, 2024.
8. U.S. Food and Drug Administration. SOPP 8216: Fast Track Development Programs - Designation and Management, Version 5. CBER, FDA, 2026.
9. Hwang TJ, Darrow JJ, Kesselheim AS. The FDA's Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016. JAMA. 2017;318(21):2137-2138.
10. Monge AN, Sigelman DW, Temple RJ, Chahal HS. Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021. JAMA Network Open. 2022;5(11):e2239336.
11. U.S. Food and Drug Administration. Frequently Asked Questions: Breakthrough Therapies. FDA, 2018.
12. U.S. Food and Drug Administration. Breakthrough Therapy. FDA, 2018.
13. U.S. Food and Drug Administration. Priority Review. FDA, 2018.